61381-04-2

Basic information

• Product Name: 3,4-Diethoxyphenethylamine
• Synonyms: TIMTEC-BB SBB001870;RARECHEM AL BW 0522;3,4-DIETHOXYBENZENE ETHANAMINE;3,4-DIETHOXYPHENETHYLAMINE;3,4-DIETHOXYPHENYLETHYLAMINE;3,4-DIETHYLOXY PHENYL ETHYLAMINE;2-(3,4-DIETHOXYPHENYL)ETHANAMINE;2-(3,4-DIETHOXY-PHENYL)-ETHYLAMINE
• CAS NO: 61381-04-2
• Molecular Formula: C₁₂H₁₉NO₂
• Molecular Weight: 209.28
• EINECS: 262-752-8
• Mol File: 61381-04-2.mol

Chemical Properties

• Boiling Point: 311.4 °C at 760 mmHg
• Flash Point: 155.2 °C
• Appearance: Colorless to yellow clear liquid
• Density: 1.011 g/cm³
• Vapor Pressure: 0.000563mmHg at 25°C
• PKA: 9.75±0.10(Predicted)
• CAS DataBase Reference: 3,4-Diethoxyphenethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Diethoxyphenethylamine(61381-04-2)
• EPA Substance Registry System: 3,4-Diethoxyphenethylamine(61381-04-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 61381-04-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
3,4-Diethoxyphenethylamine is used as a research chemical for studying its potential effects on the central nervous system. Its psychoactive properties make it a subject of interest for understanding the mechanisms of action of phenethylamine derivatives and their potential applications in medicine.
Used in Controlled Substances Regulation:
Due to its psychoactive properties and potential for abuse, 3,4-Diethoxyphenethylamine is used as a controlled substance in many countries. Regulatory bodies monitor and restrict its availability to prevent misuse and ensure safety.
Used in Toxicology and Safety Assessments:
3,4-Diethoxyphenethylamine is used in toxicology and safety assessments to evaluate its potential risks and side effects. Limited scientific research on its safety and efficacy necessitates thorough evaluation to determine its suitability for medical use.

InChI:InChI=1/C12H19NO2/c1-3-14-11-6-5-10(7-8-13)9-12(11)15-4-2/h5-6,9H,3-4,7-8,13H2,1-2H3/p+1

Upstream product

• 75332-49-9 3,4-diethoxy-trans-cinnamic acid ethyl ester 
• 1075748-15-0 tert-butyl N-[2-(3,4-diethoxyphenyl)ethyl]carbamate 
• 38464-04-9 3,4-diethoxy-phenyl-acetic acid 
• 53017-34-8 ethyl 2-(3,4-diethoxyphenyl)-2-oxoacetate 
• 2050-46-6 1,2-diethoxybenzene 
• 1137-71-9 1-(3,4-diethoxyphenyl)ethanone 
• 526190-09-0 2-(3,4-diethoxyphenyl)acetamide 
• 92157-09-0 methyl 2-(3,4-diethoxyphenyl)acetate 
• 69373-87-1 ethyl 2-(3,4-diethoxyphenyl)acetate 
• 1005009-95-9 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 279262-08-7 3,4-diethoxyphenylboronic acid 
• 53207-08-2 4-bromo-1,2-diethoxybenzene 
• 17345-77-6 1-bromo-3,4-dihydroxybenzene 
• 37034-31-4 N-(tert-butoxycarbonyl)dopamine 

Downstream Products

• 63905-65-7 6,7-diethoxy-1,2,3,4-tetrahydro-isoquinoline; hydrochloride 
• 101785-63-1 nicotinic acid-(3,4-diethoxy-phenethylamide) 
• 102708-64-5 N-(3,4-diethoxy-phenethyl)-heptanamide 
• 102012-61-3 (6,7-diethoxy-3,4-dihydro-isoquinolin-1-yl)-phenyl-methanone 
• 690697-07-5 3,4,5-trimethoxy-benzoic acid-(3,4-diethoxy-phenethylamide) 
• 94914-42-8 6,7-Diaethoxy-1-phenyl-1,2,3,4-tetrahydro-isochinolin 
• 102178-92-7 3,5-dinitro-benzoic acid-(3,4-diethoxy-phenethylamide) 
• 94311-02-1 6,7-Diethoxy-1-phenyl-3,4-dihydroisochinolin 
• 1075748-16-1 [2-(3,4-diethoxyphenyl)ethyl]ethylamine 
• 1171066-91-3 C₂₁H₂₂F₃NO₂ 
• 1190130-46-1 6,7-diethoxy-1-(4-nitrobenzyl)-1-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline 
• 1190130-47-2 6,7-diethoxy-1-(4-chlorobenzyl)-1-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline 
• 1220527-04-7 C₃₁H₂₉Cl₃N₂O₂ 

Relevant articles and documents

Novel method for preparing drotaverine hydrochloride intermediate

The invention discloses a novel method for preparing a drotaverine hydrochloride intermediate, belonging to the technical field of medicine synthesis. The preparation method comprises the following steps: preparing an intermediate 3,4-diethoxyphenylacetic acid with 1,2-diethoxybenzene as a raw material, and preparing the intermediate 3,4-diethoxyphenylacetamide with 3,4-diethoxyphenylacetic acid as a raw material. According to the novel process for preparing the drotaverine hydrochloride intermediate, a method for directly preparing 3,4-diethoxyphenylacetic acid and 3,4-diethoxyphenylethylamine is adopted, and a process for preparing 3,4-diethoxyphenylacetonitrile is avoided, so a reaction step of using sodium cyanide is avoided.

Novel preparation method of drotaverine hydrochloride intermediate

The invention discloses a novel preparation method of a drotaverine hydrochloride intermediate. The preparation method comprises the steps that 1, 4-bromopyrocatechol serves as the raw material and issubjected to an ethylation reaction under the action of iodoethane or diethyl sulfate, and 1,2-diethoxy-4-bromobenzene is prepared; 2, 1,2-diethoxy-4-bromobenzene is subjected to a Suzuki-Miyaura coupling reaction and reacts with ethyl bromoacetate or methyl bromoacetate to prepare 3,4-diethoxyphenylaceticacid ester; 3, 3,4-diethoxyphenylaceticacid is hydrolyzed to prepare 3,4-diethoxyphenylaceticacid; 4, 3,4-diethoxyphenylaceticacid ester and ammonia are prepared into 3,4-diethoxyphenylacetamide; 5, 3,4-diethoxyphenylacetamide is reduced to prepare 3,4-diethoxyphenethylamine. The direct preparation method is used; in the process of preparing 3,4-diethoxyphenyl acetonitrile, application of sodium cyanide is avoided; when 3,4-diethoxyphenethylamine is prepared, lithium aluminium hydride isused for reduction, and a pressurized hydrogenation method is prevented from being used, so that the problems about safety and environment pollution are effectively solved, the process is simple andeasy to implement, and the practicality is high.

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.

BRIDGED SIX-MEMBERED RING COMPOUNDS

The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

Process for the preparation of (8As,12AS,13AS)-decahydroisoquino ((2,1-G) (1,6)-naphthyridin-8-one derivatives

The invention provides a process for preparing single enantiomers of compounds represented by the formula: STR1 and chiral acid addition salts thereof; wherein: X and Y are independently hydrogen; lower alkyl; lower alkoxy; or halo; or X and Y taken together is methylenedioxy or ethylene-1,2-dioxy; which includes reduction of a compound represented by the formula: STR2 to give a mixture of stereoisomers represented by the formula: STR3 wherein each wavy line independently represents a bond in either the α or β position; followed by dissolving the mixture of stereoisomers and a chiral resolving acid in a suitable solvent and allowing the solution to crystallize, giving a salt of the desired enantiomer.